Healthcare -
Biotechnology - NASDAQ - IE
$ 0.874
-6.47 %
$ 35 M
Market Cap
-0.98
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
Iterum Therapeutics plc
| Current Assets | 24.8 M |
| Cash & Short-Term Investments | 24.1 M |
| Receivables | 66 K |
| Other Current Assets | 596 K |
| Non-Current Assets | 19.8 M |
| Long-Term Investments | 0 |
| PP&E | 23 K |
| Other Non-Current Assets | 19.8 M |
| Current Liabilities | 17.6 M |
| Accounts Payable | 251 K |
| Short-Term Debt | 14.5 M |
| Other Current Liabilities | 2.89 M |
| Non-Current Liabilities | 31.1 M |
| Long-Term Debt | 31.1 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Iterum Therapeutics plc
| Revenue | 0 |
| Cost Of Revenue | 254 K |
| Gross Profit | -254 K |
| Operating Expenses | 18.4 M |
| Operating Income | -18.7 M |
| Other Expenses | 6.08 M |
| Net Income | -24.8 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Iterum Therapeutics plc
| Net Income | -24.8 M |
| Depreciation & Amortization | 284 K |
| Capital Expenditures | -2 K |
| Stock-Based Compensation | 363 K |
| Change in Working Capital | -12.7 M |
| Others | 2.1 M |
| Free Cash Flow | -26.8 M |
Wall Street Analysts Price Targets
Iterum Therapeutics plc
ITRM has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
ITRM does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Iterum Therapeutics plc
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN and CHICAGO, July 02, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum” or the “Company”), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced that it has granted a non-statutory share option to purchase an aggregate of 200,000 ordinary shares of Iterum to Christine Coyne, Iterum's newly appointed Chief Commercial Officer. This grant was awarded pursuant to the Nasdaq inducement grant exception as a component of new hire employment compensation.
globenewswire.com
- 4 weeks ago
Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth
DUBLIN and CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum” or the “Company”), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced the appointment of Christine Coyne to the newly created position of Chief Commercial Officer. In this role, Ms. Coyne will lead all commercial efforts for Iterum, including the upcoming launch of ORLYNVAH™ in the United States, as well as future commercialization activities across new products and markets.
globenewswire.com
- 1 month ago
Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence
9.2% of Patients in REASSURE's Primary Population had a Baseline Pathogen Resistant to Three or More Classes of Antibiotics 9.2% of Patients in REASSURE's Primary Population had a Baseline Pathogen Resistant to Three or More Classes of Antibiotics
globenewswire.com
- 1 month ago
Iterum Therapeutics Announces Partnership for Commercialization Services
U.S. Commercial Launch of ORLYNVAH TM by Q4 2025; First Oral Penem Available in the U.S. Management to host a conference call at 4:30 p.m. ET today DUBLIN and CHICAGO, June 11, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that it entered into a Product Commercialization Agreement (the “Agreement”) with EVERSANA Life Science Services, LLC (“EVERSANA”) for the commercialization of the Company's approved product, ORLYNVAHTM.
globenewswire.com
- 1 month ago
Iterum Therapeutics Announces Extension of Term of Promissory Note
DUBLIN and CHICAGO, May 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that Pfizer Inc. (“Pfizer”) has agreed to extend the term for payment of the regulatory milestone payment of $20.0 million until October 25, 2029.
globenewswire.com
- 2 months ago
Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Call Transcript
Iterum Therapeutics plc (NASDAQ:ITRM ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Louise Barrett - SVP, Legal Affairs Corey Fishman - Chief Executive Officer Judy Matthews - Chief Financial Officer Conference Call Participants Matthew Keller - H.C. Wainwright Operator Hello, everyone, and thank you for joining the Iterum Therapeutics plc First Quarter 2025 Earnings and Business Update Call.
seekingalpha.com
- 2 months ago
Iterum Therapeutics Reports First Quarter 2025 Financial Results
--Preparing for Potential Launch of ORLYNVAH TM by Q4 2025-- - -Extended Cash Runway into 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, May 13, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the first quarter ended March 31, 2025. “Based on pre-commercialization work completed to date, we expect to be able to launch ORLYNVAHTM for the treatment of uncomplicated urinary tract infections (uUTIs) by the fourth quarter of this year,” said Corey Fishman, Iterum's Chief Executive Officer.
globenewswire.com
- 2 months ago
Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025
DUBLIN, Ireland and CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its first quarter 2025 financial results before the open of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call at 8:30 a.m.
globenewswire.com
- 2 months ago
Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares
DUBLIN, Ireland and CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today closed the previously announced purchase and sale of an aggregate of 5,555,556 ordinary shares (or pre-funded warrants in lieu thereof) at a purchase price of $0.90 per ordinary share (or pre-funded warrant in lieu thereof) in a registered direct offering (the Offering) with a single institutional investor.
globenewswire.com
- 3 months ago
Iterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary Shares
DUBLIN, Ireland and CHICAGO, April 29, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of an aggregate of 5,555,556 ordinary shares (or pre-funded warrants in lieu thereof) at a purchase price of $0.90 per ordinary share (or pre-funded warrant in lieu thereof) in a registered direct offering (the Offering). The closing of the Offering is expected to occur on or about April 30, 2025, subject to the satisfaction of customary closing conditions.
globenewswire.com
- 3 months ago
Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics
DUBLIN and CHICAGO, April 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that one poster was presented at the 35th Annual European Congress of Clinical Microbiology and Infectious Disease (ECCMID) held in Vienna, Austria, from April 11-15, 2025.
globenewswire.com
- 3 months ago
Iterum Therapeutics plc (ITRM) Q4 2024 Earnings Call Transcript
Iterum Therapeutics plc (NASDAQ:ITRM ) Q4 2024 Earnings Conference Call February 7, 2025 8:30 AM ET Company Participants Louise Barrett - SVP, Legal Affairs Corey Fishman - CEO Judy Matthews - CFO Conference Call Participants Thomas Yip - H.C. Wainwright Operator Hello, everyone.
seekingalpha.com
- 5 months ago
8. Profile
Summary
Iterum Therapeutics plc ITRM
COUNTRY
IE
INDUSTRY
Biotechnology
MARKET CAP
$ 35 M
Dividend Yield
0.00%
Description
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Contact
Fitzwilliam Court, Dublin, 2
https://www.iterumtx.com
IPO
Date
May 25, 2018
Employees
9
Officers
Mr. Corey N. Fishman
President, Chief Executive Officer & Director
Dr. Steven I. Aronin M.D.
Senior Vice President & Head of Clinical Development
Mr. Tom Loughman Ph.D.
Senior Vice President of Technical Operations
Dr. Michael W. Dunne M.D.
Strategic Advisor & Director
Ms. Judith M. Matthews
Chief Financial Officer
Ms. Louise Barrett
Senior Vice President of Legal Affairs & Secretary